Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer.

ABSTRACT: The identification of clinically important molecular mechanisms driving endocrine resistance is a priority in estrogen receptor-positive (ER+) breast cancer. Although both genomic and non-genomic cross-talk between the ER and growth factor receptors such as human epidermal growth factor receptor 2 (HER2) has frequently been associated with both experimental and clinical endocrine therapy resistance, combined targeting of ER and HER2 has failed to improve overall survival in endocrine non-responsive disease. Herein, we questioned the role of fatty acid synthase (FASN), a lipogenic enzyme linked to HER2-driven breast cancer aggressiveness, in the development and maintenance of hormone-independent growth and resistance to anti-estrogens in ER/HER2-positive (ER+/HER2+) breast cancer. The stimu

SUBMITTER: Menendez JA 

PROVIDER: S-EPMC7961649 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature